Live
Novo NordiskNovo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - simplywall.stEurofinsEurofins Scientific SE Stock (FR0014000MR3): stock in focus after quiet trading week - AD HOC NEWSCellMechanism of lipid transfer by bridge-like protein VPS13A and the scramblase XKCellGregory J. Hannon (1964–2026)FierceBiotechLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’Eli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - investor.lilly.comEli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - PR NewswireEli LillyLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ - Fierce BiotechEli LillyAbridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion - Healthcare DiveEndpoints NewsBiopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and moreClinical OMICsLong-Read DNA Test Could Replace 15 Existing Tests for Rare Diseases10x Genomics Blog10x Genomics (TXG) Stock Valuation After Recent Surge In Returns - simplywall.st
BioWorld 10. März 2026

Synnocare Pharmaceutical discloses DHX9 inhibitors

Synnocare Pharmaceutical discloses DHX9 inhibitors

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.